My commentary on the National Institutes of Health's Office of Scientific Integrity in the May 13, 1991, issue of The Scientist [page 12] referred to its overreaction to political pressure in combating fraud. I think it's important to add a mention of some related history. In an earlier era of red-baiting, NIH refused to award grants to such distinguished scientists as Linus Pauling and Elvin Kabat, because they were accused (without trial) of misconduct. Because most readers are probably not
Because most readers are probably not aware of that shameful history, I am grateful to The Scientist for publishing this addendum. In evaluating current reactions to congressional pressure, a concrete example of an earlier mistake may be more useful than abstract arguments.
BERNARD D. DAVIS
Microbiology Department
Harvard Medical School
Boston
When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.
View this Issue
In this half-day virtual summit, a series of presentations will explore the scientific, regulatory, and operational factors impacting the use of in vitro NAMs in drug discovery.
In this webinar, scientists will discuss innovations that are unlocking new insights into immunity.
In this webinar, Magdalena Pacewicz will highlight how to use AUC to characterize AAVs as part of ensuring regulatory compliance.
Discover how the latest cancer research models and their applications help scientists pursue breakthrough cancer therapy research.
Chief Business Officer Dr. Rob Burgess Shares How Sino Biological Is Empowering Global Biomedical Research Through Precision, Quality, and Innovation on an Exclusive Segment on Fox Business Network airing on February 1, 2026 at 4:30pm EST
Sino Biological, Inc. has announced the accelerated availability and development of critical research tools to support the global scientific community in combating NiV.
Collaboration will bring next generation orchestration and modular automation to scientists worldwide
The ranking places Refeyn among a cohort of high-growth UK technology firms spanning sectors including the life sciences, energy and sustainability, telecommunications, and digital technology.
